

Catia Cilloniz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4620254/publications.pdf>

Version: 2024-02-01

451
papers

24,224
citations

9756

73
h-index

10127

140
g-index

487
all docs

487
docs citations

487
times ranked

18673
citing authors

#	ARTICLE	IF	CITATIONS
1	Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. <i>Lancet, The</i> , 1999, 354, 1851-1858.	6.3	1,254
2	Incidence, Risk, and Prognosis Factors of Nosocomial Pneumonia in Mechanically Ventilated Patients. <i>The American Review of Respiratory Disease</i> , 1990, 142, 523-528.	2.9	874
3	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. <i>European Respiratory Journal</i> , 2017, 50, 1700582.	3.1	792
4	European Respiratory Society guidelines for the management of adult bronchiectasis. <i>European Respiratory Journal</i> , 2017, 50, 1700629.	3.1	788
5	Significance of the Isolation of <i>Candida</i> Species from Respiratory Samples in Critically Ill, Non-neutropenic Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 583-590.	2.5	717
6	Bacterial Colonization Patterns in Mechanically Ventilated Patients with Traumatic and Medical Head Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 188-198.	2.5	583
7	Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors. <i>The American Review of Respiratory Disease</i> , 1991, 144, 312-318.	2.9	564
8	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <i>Lancet Respiratory Medicine</i> , 2014, 2, 395-404.	5.2	527
9	Risk factors for community-acquired pneumonia in adults in Europe: a literature review. <i>Thorax</i> , 2013, 68, 1057-1065.	2.7	489
10	Bronchial Microbial Patterns in Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 1498-1505.	2.5	430
11	Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 677.	3.8	428
12	Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. <i>Thorax</i> , 1999, 54, 867-873.	2.7	416
13	Defining, treating and preventing hospital acquired pneumonia: European perspective. <i>Intensive Care Medicine</i> , 2009, 35, 9-29.	3.9	397
14	Community-acquired pneumonia. <i>Lancet, The</i> , 2015, 386, 1097-1108.	6.3	392
15	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. <i>Lancet Respiratory Medicine</i> , 2021, 9, 622-642.	5.2	371
16	Addition of a Macrolide to a β -Lactam-Based Empirical Antibiotic Regimen Is Associated with Lower In-Hospital Mortality for Patients with Bacteremic Pneumococcal Pneumonia. <i>Clinical Infectious Diseases</i> , 2003, 36, 389-395.	2.9	355
17	Community-Acquired Pneumonia Due to Gram-Negative Bacteria and <i>Pseudomonas aeruginosa</i> . <i>Archives of Internal Medicine</i> , 2002, 162, 1849.	4.3	335
18	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 285-295.	4.6	300

#	ARTICLE	IF	CITATIONS
19	Microbial aetiology of community-acquired pneumonia and its relation to severity. <i>Thorax</i> , 2011, 66, 340-346.	2.7	259
20	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. <i>European Respiratory Journal</i> , 2017, 49, 1700051.	3.1	253
21	Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. <i>Intensive Care Medicine</i> , 2021, 47, 188-198.	3.9	237
22	Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1764-1770.	1.5	233
23	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021, 7, 25.	18.1	230
24	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table 1. <i>Thorax</i> , 2015, 70, 984-989.	2.7	224
25	Current gaps in sepsis immunology: new opportunities for translational research. <i>Lancet Infectious Diseases</i> , 2019, 19, e422-e436.	4.6	205
26	Rethinking the concepts of community-acquired and health-care-associated pneumonia. <i>Lancet Infectious Diseases</i> , 2010, 10, 279-287.	4.6	196
27	Programmed "disarming" of the neutrophil proteome reduces the magnitude of inflammation. <i>Nature Immunology</i> , 2020, 21, 135-144.	7.0	180
28	Pneumonia Acquired in the Community Through Drug-Resistant <i>Streptococcus pneumoniae</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 159, 1835-1842.	2.5	171
29	Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2120.	1.8	168
30	Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19. <i>Chest</i> , 2021, 160, 187-198.	0.4	164
31	Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia. <i>Chest</i> , 2013, 144, 999-1007.	0.4	162
32	Nosocomial Pneumonia in the Intensive Care Unit Acquired by Mechanically Ventilated versus Nonventilated Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1533-1539.	2.5	160
33	Increased incidence of co-infection in critically ill patients with influenza. <i>Intensive Care Medicine</i> , 2017, 43, 48-58.	3.9	159
34	The Role of Neutrophil Elastase Inhibitors in Lung Diseases. <i>Chest</i> , 2017, 152, 249-262.	0.4	158
35	Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission. <i>Clinical Infectious Diseases</i> , 2009, 48, 377-385.	2.9	154
36	Impact of Alcohol Abuse in the Etiology and Severity of Community-Acquired Pneumonia. <i>Chest</i> , 2006, 129, 1219-1225.	0.4	144

#	ARTICLE	IF	CITATIONS
37	New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1287-1297.	2.5	142
38	High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure. <i>Critical Care</i> , 2021, 25, 58.	2.5	138
39	Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015, 12, 153-160.	1.5	136
40	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016, 2, 00081-2015.	1.1	133
41	Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia*. <i>Critical Care Medicine</i> , 2004, 32, 938-945.	0.4	132
42	Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table A1. <i>Thorax</i> , 2013, 68, 997-999.	2.7	129
43	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. <i>Intensive Care Medicine</i> , 2018, 44, 1470-1482.	3.9	123
44	Burden and risk factors for <i>Pseudomonas aeruginosa</i> community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018, 52, 1701190.	3.1	122
45	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. <i>The Lancet Global Health</i> , 2019, 7, e1269-e1279.	2.9	116
46	Prognostic Factors of Severe <i>Legionella</i> Pneumonia Requiring Admission to ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 1467-1472.	2.5	115
47	The Role of Viruses in the Aetiology of Community-Acquired Pneumonia in Adults. <i>Antiviral Therapy</i> , 2006, 11, 351-359.	0.6	110
48	Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. <i>Journal of Infection</i> , 2016, 72, 143-151.	1.7	108
49	Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines. <i>Archives of Internal Medicine</i> , 2009, 169, 1515.	4.3	106
50	Laboratory diagnosis of pneumonia in the molecular age. <i>European Respiratory Journal</i> , 2016, 48, 1764-1778.	3.1	106
51	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. <i>Chest</i> , 2020, 158, 1896-1911.	0.4	105
52	Pneumonia Severity Index Class V Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2007, 132, 515-522.	0.4	103
53	Challenges in severe community-acquired pneumonia: a point-of-view review. <i>Intensive Care Medicine</i> , 2019, 45, 159-171.	3.9	100
54	Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. <i>Critical Care</i> , 2011, 15, R209.	2.5	99

#	ARTICLE	IF	CITATIONS
55	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 346-354.	2.9	98
56	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). <i>Intensive Care Medicine</i> , 2018, 44, 438-448.	3.9	96
57	Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2010, 51, S48-S53.	2.9	95
58	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016, 20, 133.	2.5	94
59	The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 139-152.	1.0	92
60	Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. <i>Translational Research</i> , 2021, 236, 147-159.	2.2	91
61	Pneumonic and Nonpneumonic Exacerbations of COPD. <i>Chest</i> , 2013, 144, 1134-1142.	0.4	90
62	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. <i>Respiratory Medicine</i> , 2018, 137, 6-13.	1.3	90
63	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020, 80, e23-e24.	1.7	89
64	Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia. <i>Chest</i> , 2012, 141, 1537-1545.	0.4	86
65	Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Chest</i> , 2016, 150, 415-425.	0.4	85
66	Community-acquired pneumonia related to intracellular pathogens. <i>Intensive Care Medicine</i> , 2016, 42, 1374-1386.	3.9	85
67	Intensive care unit-acquired pneumonia due to <i>Pseudomonas aeruginosa</i> with and without multidrug resistance. <i>Journal of Infection</i> , 2017, 74, 142-152.	1.7	83
68	Diagnosing Ventilator-Associated Pneumonia. <i>New England Journal of Medicine</i> , 2004, 350, 433-435.	13.9	82
69	A Prediction Rule for Estimating the Risk of Bacteremia in Patients with Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2009, 49, 409-416.	2.9	82
70	Nosocomial Infection. <i>Critical Care Medicine</i> , 2021, 49, 169-187.	0.4	82
71	Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. <i>PLoS ONE</i> , 2018, 13, e0191721.	1.1	81
72	Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia. <i>Critical Care</i> , 2019, 23, 79.	2.5	78

#	ARTICLE	IF	CITATIONS
73	Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. <i>Journal of Infection</i> , 2012, 65, 223-230.	1.7	77
74	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, caseâ€“control study. <i>Thorax</i> , 2013, 68, 1007-1014.	2.7	77
75	New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. <i>Current Opinion in Critical Care</i> , 2018, 24, 347-352.	1.6	77
76	Moxifloxacin Monotherapy Is Effective in Hospitalized Patients with Communityâ€“Acquired Pneumonia: The MOTIV Studyâ€“A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2008, 46, 1499-1509.	2.9	75
77	Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study. <i>PLoS ONE</i> , 2016, 11, e0150737.	1.1	72
78	Decrease in Mortality in Severe Community-Acquired Pneumococcal Pneumonia. <i>Chest</i> , 2014, 146, 22-31.	0.4	71
79	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2022, 10, 298-306.	5.2	70
80	Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. <i>EBioMedicine</i> , 2017, 24, 231-236.	2.7	69
81	Pulmonary infections complicating ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2168-2183.	3.9	69
82	Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. <i>Translational Research</i> , 2021, 232, 60-74.	2.2	69
83	Epidemiology of ICU-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018, 24, 325-331.	1.6	67
84	Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5520-5528.	1.4	66
85	Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 546-556.	2.5	65
86	Community-acquired pneumonia in outpatients: aetiology and outcomes. <i>European Respiratory Journal</i> , 2012, 40, 931-938.	3.1	64
87	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016, 11, e0145929.	1.1	61
88	Management of severe acute exacerbations of COPD: an updated narrative review. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 36.	0.6	61
89	Validation of Predictors of Adverse Outcomes in Hospital-Acquired Pneumonia in the ICU*. <i>Critical Care Medicine</i> , 2013, 41, 2151-2161.	0.4	60
90	The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for <i>Streptococcus pneumoniae</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1265-1272.	2.5	59

#	ARTICLE	IF	CITATIONS
91	Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. <i>Chest</i> , 2017, 151, 47-59.	0.4	59
92	Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. <i>European Respiratory Journal</i> , 2014, 43, 1698-1708.	3.1	58
93	Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. <i>Intensive Care Medicine</i> , 2014, 40, 572-581.	3.9	57
94	Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients. <i>Critical Care</i> , 2011, 15, R286.	2.5	56
95	Mechanisms of Abnormal Gas Exchange in Patients with Pneumonia. <i>Anesthesiology</i> , 1991, 75, 782-789.	1.3	54
96	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. <i>Cytokine</i> , 2016, 88, 267-273.	1.4	54
97	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 192-204.	1.5	54
98	Aerosolized β_2 -agonists in the intensive care unit: just do it. <i>Intensive Care Medicine</i> , 2001, 27, 3-5.	3.9	53
99	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUNGAL</sc> infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	1.8	53
100	Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 469-481.	0.8	52
101	Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1482-1489.	1.5	51
102	Systemic Inflammatory Pattern of Patients With Community-Acquired Pneumonia With and Without COPD. <i>Chest</i> , 2013, 143, 1009-1017.	0.4	49
103	<i>Pneumocystis</i> pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 787-801.	2.0	49
104	Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. <i>Journal of Infectious Diseases</i> , 2019, 219, 1536-1544.	1.9	49
105	Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1241-1248.	2.5	48
106	Effects of bronchoalveolar lavage volume on arterial oxygenation in mechanically ventilated patients with pneumonia. <i>Intensive Care Medicine</i> , 2001, 27, 384-393.	3.9	47
107	Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia. <i>Chest</i> , 2013, 143, 767-775.	0.4	47
108	Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data. <i>Annals of Intensive Care</i> , 2015, 5, 43.	2.2	47

#	ARTICLE	IF	CITATIONS
109	Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2018, 51, 1702215.	3.1	45
110	Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. <i>Journal of Infection</i> , 2019, 78, 423-431.	1.7	45
111	The BRICS (Bronchiectasis Radiologically Indexed CT Score). <i>Chest</i> , 2018, 153, 1177-1186.	0.4	44
112	Seasonality of pathogens causing community-acquired pneumonia. <i>Respirology</i> , 2017, 22, 778-785.	1.3	43
113	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020, 282, 103529.	0.7	43
114	Community-acquired pneumonia in critically ill very old patients: a growing problem. <i>European Respiratory Review</i> , 2020, 29, 190126.	3.0	43
115	Importance of <i>Aspergillus</i> spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. <i>Respiratory Research</i> , 2014, 15, 17.	1.4	42
116	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , 2015, 45, 1353-1363.	3.1	42
117	What is the clinical relevance of drug-resistant pneumococcus?. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 227-234.	1.2	42
118	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. <i>Chest</i> , 2018, 154, 798-807.	0.4	42
119	A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia. <i>Respiratory Care</i> , 2014, 59, 1078-1085.	0.8	41
120	Polymicrobial intensive care unit-acquired pneumonia: prevalence, microbiology and outcome. <i>Critical Care</i> , 2015, 19, 450.	2.5	41
121	A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. <i>Clinical Infectious Diseases</i> , 2018, 66, 1222-1229.	2.9	41
122	Community-acquired pneumonia as an emergency condition. <i>Current Opinion in Critical Care</i> , 2018, 24, 531-539.	1.6	41
123	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018, 4, 00028-2018.	1.1	41
124	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. <i>Critical Care Medicine</i> , 2021, 49, 503-516.	0.4	41
125	Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 370-378.	2.5	40
126	Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. <i>Chest</i> , 2019, 156, 1080-1091.	0.4	40

#	ARTICLE	IF	CITATIONS
127	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. <i>Respiratory Research</i> , 2014, 15, 27.	1.4	39
128	Declining Mortality in Patients With Acute Respiratory Distress Syndrome: An Analysis of the Acute Respiratory Distress Syndrome Network Trials. <i>Critical Care Medicine</i> , 2019, 47, 315-323.	0.4	39
129	Biomarkers and Community-Acquired Pneumonia: Tailoring Management with Biological Data. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 266-271.	0.8	37
130	Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation â€œ The CIGMA study. <i>Respiratory Medicine</i> , 2015, 109, 758-767.	1.3	37
131	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , 2016, 47, 1635-1644.	3.1	37
132	Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study. <i>Journal of Intensive Care</i> , 2021, 9, 23.	1.3	37
133	Association between systemic corticosteroids and outcomes of intensive care unitâ€œacquired pneumonia*. <i>Critical Care Medicine</i> , 2012, 40, 2552-2561.	0.4	36
134	Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia. <i>European Respiratory Journal</i> , 2016, 48, 797-807.	3.1	36
135	Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , 2017, 43, 1572-1584.	3.9	36
136	Phenotypic shift in <i>Pseudomonas aeruginosa</i> populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 222-229.	0.3	36
137	The importance of airway and lung microbiome in the critically ill. <i>Critical Care</i> , 2020, 24, 537.	2.5	36
138	Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDAâ€œSpecified End Points. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz149.	0.4	35
139	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100041.	3.0	35
140	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1190-1197.	1.0	34
141	Pneumococcal vaccination. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 187-196.	1.3	34
142	Effect of Combined β -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2019, 155, 795-804.	0.4	34
143	NeumonÃ±a adquirida en la comunidad. Normativa de la Sociedad EspaÃ±ola de NeumologÃ±a y CirugÃ±a TorÃ¡cica (SEPAR). ActualizaciÃ³n 2020. <i>Archivos De Bronconeumologia</i> , 2020, 56, 1-10.	0.4	34
144	Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia. <i>PLoS ONE</i> , 2014, 9, e110566.	1.1	34

#	ARTICLE	IF	CITATIONS
145	Update in Community-acquired and Nosocomial Pneumonia 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 782-787.	2.5	32
146	Therapy with protonâ€pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respiriology, 2016, 21, 883-890.	1.3	32
147	Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 281-289.	0.7	32
148	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. PLoS ONE, 2017, 12, e0175171.	1.1	32
149	Gender differences in community-acquired pneumonia. Minerva Medica, 2020, 111, 153-165.	0.3	32
150	Systemic corticosteroids for communityâ€acquired pneumonia: Reasons for use and lack of benefit on outcome. Respiriology, 2013, 18, 263-271.	1.3	31
151	Polymicrobial communityâ€acquired pneumonia: An emerging entity. Respiriology, 2016, 21, 65-75.	1.3	31
152	An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria. Current Opinion in Infectious Diseases, 2019, 32, 656-662.	1.3	31
153	A multicentre analysis of Nocardia pneumonia in Spain: 2010â€2016. International Journal of Infectious Diseases, 2020, 90, 161-166.	1.5	31
154	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011â€2018. Clinical Infectious Diseases, 2021, 73, 1075-1085.	2.9	31
155	IgM levels in plasma predict outcome in severe pandemic influenza. Journal of Clinical Virology, 2013, 58, 564-567.	1.6	30
156	Importance of Legionella pneumophila in the Etiology of Severe Community-Acquired Pneumonia in Santiago, Chile. Chest, 2014, 145, 290-296.	0.4	30
157	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. Respiratory Research, 2017, 18, 176.	1.4	30
158	A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	30
159	Pure Viral Sepsis Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors. Journal of Infectious Diseases, 2019, 220, 1166-1171.	1.9	30
160	Can Artificial Intelligence Improve the Management of Pneumonia. Journal of Clinical Medicine, 2020, 9, 248.	1.0	30
161	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respiratory Medicine, 2015, 109, 743-750.	1.3	29
162	Impact of amoxicillin therapy on resistance selection in patients with community-acquired lower respiratory tract infections: a randomized, placebo-controlled study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3258-3267.	1.3	29

#	ARTICLE	IF	CITATIONS
163	Serum levels of immunoglobulins and severity of community-acquired pneumonia. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000152.	1.2	29
164	Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 35.	1.3	29
165	Evaluation of the Magicplexâ„¢ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 56.	1.8	29
166	Lung ultrasound in the evaluation of pleural effusion. <i>Jornal Brasileiro De Pneumologia</i> , 2014, 40, 1-5.	0.4	28
167	Clinical variables predicting the risk of a hospital stay for longer than 7â€%days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. <i>Respiratory Research</i> , 2018, 19, 261.	1.4	28
168	SARS-CoV-2â€“induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1164-1168.	1.5	28
169	Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. <i>PLoS ONE</i> , 2017, 12, e0182436.	1.1	28
170	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017, 17, 659.	1.3	27
171	Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. <i>PLoS ONE</i> , 2018, 13, e0200504.	1.1	27
172	Serum levels of hyaluronic acid are associated with COPD severity and predict survival. <i>European Respiratory Journal</i> , 2019, 53, 1801183.	3.1	27
173	Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019, 8, 843.	1.0	27
174	Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1651-1659.	1.3	26
175	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019, 60, 54-70.	1.0	26
176	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. <i>Chest</i> , 2020, 158, 1912-1918.	0.4	26
177	Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1037.e1-1037.e8.	2.8	26
178	The clinical positioning of telavancin in Europe. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 213-220.	1.1	25
179	Clinical management of community acquired pneumonia in the elderly patient. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1211-1220.	1.0	25
180	Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome. <i>Journal of Infection</i> , 2016, 73, 419-426.	1.7	25

#	ARTICLE	IF	CITATIONS
181	Severe flu management: a point of view. <i>Intensive Care Medicine</i> , 2020, 46, 153-162.	3.9	25
182	Q Fever (<i>Coxiella Burnetii</i>). <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 509-521.	0.8	25
183	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0178022.	1.1	25
184	Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. <i>Annals of Translational Medicine</i> , 2017, 5, 443-443.	0.7	25
185	Impact of exposure time in awake prone positioning on clinical outcomes of patients with COVID-19-related acute respiratory failure treated with high-flow nasal oxygen: a multicenter cohort study. <i>Critical Care</i> , 2022, 26, 16.	2.5	25
186	Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study. <i>BMJ Open</i> , 2014, 4, e005133-e005133.	0.8	24
187	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. <i>Respiratory Research</i> , 2014, 15, 75.	1.4	24
188	Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial. <i>European Respiratory Journal</i> , 2017, 50, 1601448.	3.1	24
189	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 69, 1912-1918.	2.9	24
190	Invasive and non-invasive diagnostic approaches for microbiological diagnosis of hospital-acquired pneumonia. <i>Critical Care</i> , 2019, 23, 51.	2.5	24
191	Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome. <i>EBioMedicine</i> , 2020, 60, 102995.	2.7	24
192	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. <i>European Respiratory Review</i> , 2021, 30, 200346.	3.0	24
193	Aspiration pneumonia: A renewed perspective and practical approach. <i>Respiratory Medicine</i> , 2021, 185, 106485.	1.3	24
194	Endotracheal Tubes for Critically Ill Patients. <i>Chest</i> , 2015, 147, 1327-1335.	0.4	23
195	New aspects in the management of pneumonia. <i>Critical Care</i> , 2016, 20, 267.	2.5	23
196	Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. <i>Journal of Critical Care</i> , 2017, 41, 91-97.	1.0	23
197	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. <i>Vaccine</i> , 2017, 35, 5264-5270.	1.7	23
198	Emerging antibiotics for community-acquired pneumonia. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 221-231.	1.0	23

#	ARTICLE	IF	CITATIONS
199	Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?. <i>European Respiratory Review</i> , 2020, 29, 200023.	3.0	23
200	Assessment of a Loop-Mediated Isothermal Amplification (LAMP) Assay for the Rapid Detection of Pathogenic Bacteria from Respiratory Samples in Patients with Hospital-Acquired Pneumonia. <i>Microorganisms</i> , 2020, 8, 103.	1.6	23
201	The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. <i>Critical Care</i> , 2021, 25, 331.	2.5	23
202	Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition. <i>Intensive Care Medicine</i> , 2014, 40, 147-159.	3.9	22
203	Endotracheal tube biofilm translocation in the lateral Trendelenburg position. <i>Critical Care</i> , 2015, 19, 59.	2.5	22
204	Predicting In-Hospital Treatment Failure (≥7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 82-92.	0.7	22
205	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRI project. <i>ERJ Open Research</i> , 2017, 3, 00092-2017.	1.1	22
206	Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. <i>Lancet Respiratory Medicine</i> , 2017, 5, e35-e36.	5.2	22
207	Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019, 8, 961.	1.0	22
208	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. <i>European Journal of Internal Medicine</i> , 2017, 37, 13-18.	1.0	21
209	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. <i>Critical Care</i> , 2018, 22, 343.	2.5	21
210	Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2018, 19, 119.	1.4	21
211	Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. <i>Scientific Reports</i> , 2018, 8, 9236.	1.6	21
212	Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. <i>Intensive Care Medicine</i> , 2013, 39, 1776-1784.	3.9	20
213	Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: A prospective clinical study. <i>Respirology</i> , 2014, 19, 929-935.	1.3	20
214	Exertional Hypoxemia in Stable COPD Is Common and Predicted by Circulating Proadrenomedullin. <i>Chest</i> , 2014, 146, 328-338.	0.4	20
215	Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. <i>Journal of Infection</i> , 2015, 71, 28-36.	1.7	20
216	Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC ⁴ E): the ALIC ⁴ E protocol. <i>BMJ Open</i> , 2018, 8, e021032.	0.8	20

#	ARTICLE	IF	CITATIONS
217	Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab169.	0.4	20
218	New guidelines for severe community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 210-215.	1.2	20
219	The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, S46-S51.	2.9	19
220	PES Pathogens in Severe Community-Acquired Pneumonia. <i>Microorganisms</i> , 2019, 7, 49.	1.6	19
221	Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. <i>Respiratory Research</i> , 2015, 16, 150.	1.4	18
222	Ceftobiprole for the treatment of pneumonia: a European perspective. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4565.	2.0	18
223	A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens. <i>Clinical Therapeutics</i> , 2017, 39, 1706-1718.	1.1	18
224	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021, 18, 257-265.	1.5	18
225	Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2651.	1.0	18
226	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. <i>Journal of Infection</i> , 2018, 77, 99-106.	1.7	17
227	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 356-366.	1.9	17
228	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. <i>Critical Care</i> , 2019, 23, 251.	2.5	17
229	Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 329-334.	0.8	16
230	Molecular characterization of methicillin-resistant <i>Staphylococcus aureus</i> clinical strains from the endotracheal tubes of patients with nosocomial pneumonia. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 43.	1.5	16
231	Association between physical activity and risk of hospitalisation in bronchiectasis. <i>European Respiratory Journal</i> , 2020, 55, 1902138.	3.1	16
232	Diagnosis of Pneumonia and Monitoring of Infection Eradication. <i>Drugs</i> , 2000, 60, 1289-1302.	4.9	15
233	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients. <i>Chest</i> , 2017, 152, 295-303.	0.4	15
234	Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 233-240.	1.1	15

#	ARTICLE	IF	CITATIONS
235	Community-acquired bacterial pneumonia in adult HIV-infected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 579-588.	2.0	15
236	The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. <i>Intensive Care Medicine</i> , 2019, 45, 1753-1762.	3.9	15
237	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	1.2	15
238	A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 109-118.	1.9	15
239	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. <i>EBioMedicine</i> , 2021, 66, 103291.	2.7	15
240	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2399-2414.	1.8	15
241	635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti- <i>Pseudomonas aeruginosa</i> Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program. <i>Open Forum Infectious Diseases</i> , 2020, 7, e0277-0278.	0.4	15
242	Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. <i>Emerging Microbes and Infections</i> , 2022, 11, 1537-1549.	3.0	15
243	Severity and outcomes of community acquired pneumonia in asthmatic patients. <i>Respiratory Medicine</i> , 2014, 108, 1713-1722.	1.3	14
244	Impact of COPD in the Outcome of ICU-Acquired Pneumonia With and Without Previous Intubation. <i>Chest</i> , 2015, 147, 1530-1538.	0.4	14
245	New antimicrobial approaches to gram positive respiratory infections. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 137-143.	1.1	14
246	Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?. <i>European Respiratory Journal</i> , 2016, 48, 279-281.	3.1	14
247	Drugs that increase the risk of community-acquired pneumonia: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 991-1003.	1.0	14
248	Biomarcadores biológicos en las enfermedades respiratorias. <i>Archivos De Bronconeumologia</i> , 2022, 58, 323-333.	0.4	14
249	Upper Respiratory Symptoms Worsen over Time and Relate to Clinical Phenotype in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2015, 12, 997-1004.	1.5	13
250	Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016, 48, 257-261.	3.1	13
251	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2017, 151, 1311-1319.	0.4	13
252	Ventilator-Associated Pneumonia and PaO ₂ /FIO ₂ Diagnostic Accuracy: Changing the Paradigm?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1217.	1.0	13

#	ARTICLE	IF	CITATIONS
253	Short-Term Appraisal of the Effects and Safety of Manual Versus Ventilator Hyperinflation in an Animal Model of Severe Pneumonia. <i>Respiratory Care</i> , 2019, 64, 760-770.	0.8	13
254	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2021, 57, 79-82.	0.4	13
255	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. <i>ERJ Open Research</i> , 2021, 7, 00888-2020.	1.1	13
256	Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 156-168.	1.3	13
257	Diagnostic concordance between BioFire® FilmArray® Pneumonia Panel and culture in patients with COVID-19 pneumonia admitted to intensive care units: the experience of the third wave in eight hospitals in Colombia. <i>Critical Care</i> , 2022, 26, 130.	2.5	13
258	Noninvasive Ventilation in Withdrawal from Mechanical Ventilation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 507-518.	0.8	12
259	Hospitalized patients at risk of dying: an Intensive Care Medicine call for papers. <i>Intensive Care Medicine</i> , 2016, 42, 1-2.	3.9	12
260	Emerging drugs for nosocomial pneumonia. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 331-341.	1.0	12
261	Body Position and Ventilator-Associated Pneumonia Prevention. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 371-380.	0.8	12
262	IFN β 3/4 locus polymorphisms and IFN β 3 circulating levels are associated with COPD severity and outcomes. <i>BMC Pulmonary Medicine</i> , 2018, 18, 51.	0.8	12
263	Adjuvant therapies in critical care: steroids in community-acquired pneumonia. <i>Intensive Care Medicine</i> , 2018, 44, 478-481.	3.9	12
264	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1612-1621.	0.4	12
265	Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia: The Hidden Enemy?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1071-1073.	2.5	12
266	Promoting the use of social networks in pneumonia. <i>Pneumonia (Nathan Qld)</i> , 2020, 12, 3.	2.5	12
267	Advances in molecular diagnostic tests for pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 241-248.	1.2	12
268	Non-invasive ventilation in palliative care: a systematic review. <i>Minerva Medica</i> , 2020, 110, 555-563.	0.3	12
269	Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients. <i>European Respiratory Journal</i> , 2018, 51, 1701332.	3.1	11
270	Clinical Approach to Community-acquired Pneumonia. <i>Journal of Thoracic Imaging</i> , 2018, 33, 273-281.	0.8	11

#	ARTICLE	IF	CITATIONS
271	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. <i>Respiratory Medicine</i> , 2018, 140, 115-121.	1.3	11
272	Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 154-158.	0.8	11
273	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2022, 50, 179-189.	2.3	11
274	[Translated article] Biological Biomarkers in Respiratory Diseases. <i>Archivos De Bronconeumologia</i> , 2022, 58, T323-T333.	0.4	11
275	Inhaled Corticosteroids Do Not Influence the Early Inflammatory Response and Clinical Presentation of Hospitalized Subjects With COPD Exacerbation. <i>Respiratory Care</i> , 2014, 59, 1550-1559.	0.8	10
276	Relación de las profesiones y las condiciones laborales con la neumonía adquirida en la comunidad. <i>Archivos De Bronconeumologia</i> , 2015, 51, 627-631.	0.4	10
277	Year in review in <i>Intensive Care Medicine</i> 2014: II. ARDS, airway management, ventilation, adjuvants in sepsis, hepatic failure, symptoms assessment and management, palliative care and support for families, prognostication, organ donation, outcome, organisation and research methodology. <i>Intensive Care Medicine</i> , 2015, 41, 389-401.	3.9	10
278	Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 913-922.	0.8	10
279	Mucoid <i>Pseudomonas aeruginosa</i> alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2019, 154, 40-46.	1.3	10
280	Effects of Mechanical Insufflation-Exsufflation on Sputum Volume in Mechanically Ventilated Critically Ill Subjects. <i>Respiratory Care</i> , 2021, 66, 1371-1379.	0.8	10
281	Resistance mechanisms and molecular epidemiology of <i>Pseudomonas aeruginosa</i> strains from patients with bronchiectasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1600-1610.	1.3	10
282	Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units. <i>Archivos De Bronconeumologia</i> , 2022, 58, 22-31.	0.4	10
283	CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. <i>International Journal of Infectious Diseases</i> , 2011, 15, e822-e827.	1.5	9
284	The Strange Case of Community-Acquired Pneumonia in COPD. <i>Chest</i> , 2011, 139, 483-485.	0.4	9
285	<i>Streptococcus pneumoniae</i> -associated pneumonia complicated by purulent pericarditis: case series. <i>Jornal Brasileiro De Pneumologia</i> , 2015, 41, 389-394.	0.4	9
286	Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia. <i>Journal of Infection</i> , 2017, 74, 442-449.	1.7	9
287	Community-Acquired <i>Legionella</i> Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 958-961.	2.9	9
288	Adjunctive Therapies for Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 753-764.	0.8	9

#	ARTICLE	IF	CITATIONS
289	Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 523-533.	2.0	9
290	Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia. <i>Journal of Chemotherapy</i> , 2020, 32, 1-6.	0.7	9
291	Diagnostic accuracy of Gram staining when predicting staphylococcal hospital-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1456-1463.	2.8	9
292	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105921.	1.1	9
293	Biomarkers in the ICU: less is more? No. <i>Intensive Care Medicine</i> , 2021, 47, 97-100.	3.9	9
294	Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. <i>Journal of Infection</i> , 2021, 82, 76-83.	1.7	9
295	Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 104, 501-509.	1.5	9
296	Differences between sexes concerning COVID-19-related pneumonia. <i>Panminerva Medica</i> , 2022, 64, .	0.2	9
297	Severe Infections Due to Respiratory Viruses. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 060-074.	0.8	9
298	Fungal pneumonia, chronic respiratory diseases and glucocorticoids. <i>Medical Mycology</i> , 2006, 44, 207-211.	0.3	8
299	The research agenda in VAP/HAP: next steps. <i>Intensive Care Medicine</i> , 2017, 43, 1389-1391.	3.9	8
300	Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1239-1248.	1.9	8
301	The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 683-691.	1.0	8
302	Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 817-829.	0.8	8
303	Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy. <i>Clinical Therapeutics</i> , 2020, 42, 802-817.	1.1	8
304	Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis. <i>Thorax</i> , 2021, 76, 1020-1031.	2.7	8
305	Nosocomial pneumonia in the intensive care unit: how should treatment failure be predicted. <i>Revista Brasileira De Terapia Intensiva</i> , 2014, 26, 208-11.	0.1	8
306	Approaches to suspected ventilator-associated pneumonia: relying on our own bias. <i>Intensive Care Medicine</i> , 2001, 27, 625-628.	3.9	7

#	ARTICLE	IF	CITATIONS
307	Impact of microbial ecology on accuracy of surveillance cultures to predict multidrug resistant microorganisms causing ventilator-associated pneumonia. <i>Journal of Infection</i> , 2014, 69, 333-340.	1.7	7
308	Bacteraemia in outpatients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016, 47, 654-657.	3.1	7
309	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1461.	1.0	7
310	Entendimento da mortalidade em pneumonia pneumoc�cica bacter�mica. <i>Jornal Brasileiro De Pneumologia</i> , 2012, 38, 419-421.	0.4	7
311	Lung Abscess Due to <i>Streptococcus pneumoniae</i> : A Case Series and Brief Review of the Literature. <i>Pneumonologia I Alergologia Polska</i> , 2014, 82, 276-285.	0.6	7
312	Research in community-acquired pneumonia: the next steps. <i>Intensive Care Medicine</i> , 2017, 43, 1395-1397.	3.9	6
313	Lateral position during severe mono-lateral pneumonia: an experimental study. <i>Scientific Reports</i> , 2020, 10, 19372.	1.6	6
314	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1316-1325.	1.5	6
315	Eventos cardiovasculares tempranos y tard�os en pacientes ingresados por neumon�a adquirida en la comunidad. <i>Archivos De Bronconeumologia</i> , 2020, 56, 551-558.	0.4	6
316	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 6.	1.3	6
317	Year in review in <i>Intensive Care Medicine</i> 2014: I. Cardiac dysfunction and cardiac arrest, ultrasound, neurocritical care, ICU-acquired weakness, nutrition, acute kidney injury, and miscellaneous. <i>Intensive Care Medicine</i> , 2015, 41, 179-191.	3.9	5
318	The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe <i>Pseudomonas aeruginosa</i> pneumonia. <i>Annals of Intensive Care</i> , 2016, 6, 58.	2.2	5
319	Neces-SARI-ly?. <i>Intensive Care Medicine</i> , 2016, 42, 928-930.	3.9	5
320	Editorial Commentary: Distinguishing Postobstructive Lung Infection From Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2016, 62, 962-963.	2.9	5
321	What's new in severe community-acquired pneumonia? Corticosteroids as adjunctive treatment to antibiotics. <i>Intensive Care Medicine</i> , 2016, 42, 1276-1278.	3.9	5
322	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2017, 50, 1602306.	3.1	5
323	Is One Sample Enough? � ² -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	5
324	Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. <i>European Respiratory Journal</i> , 2020, 56, 2000773.	3.1	5

#	ARTICLE	IF	CITATIONS
325	Age is a determinant of short-term mortality in patients hospitalized for an acute exacerbation of COPD. <i>Internal and Emergency Medicine</i> , 2021, 16, 401-408.	1.0	5
326	Invasive Pneumococcal Disease Today. <i>Clinical Pulmonary Medicine</i> , 2012, 19, 191-198.	0.3	4
327	New developments in the diagnosis of VAP make bronchoalveolar lavage less useful: some considerations. <i>Intensive Care Medicine</i> , 2014, 40, 1778-1779.	3.9	4
328	Should ultrasound be included in the initial assessment of respiratory patients?. <i>Lancet Respiratory Medicine</i> , 2014, 2, 599-600.	5.2	4
329	Non-invasive ventilation in hypoxemic acute respiratory failure: is it still possible?. <i>Intensive Care Medicine</i> , 2017, 43, 243-245.	3.9	4
330	Achoo, achis, ATCHIN! Vaccine youâ€¦. <i>European Respiratory Journal</i> , 2018, 51, 1702558.	3.1	4
331	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 111-116.	1.1	4
332	Appraisal of systemic inflammation and diagnostic markers in a porcine model of VAP: secondary analysis from a study on novel preventive strategies. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 42.	0.9	4
333	ICU-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018, 24, 323-324.	1.6	4
334	Optimal approaches to preventing severe community-acquired pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1005-1018.	1.0	4
335	Influenza management with new therapies. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 215-221.	1.2	4
336	Exacerbations and Changes in Physical Activity and Sedentary Behaviour in Patients with Bronchiectasis after 1 Year. <i>Journal of Clinical Medicine</i> , 2021, 10, 1190.	1.0	4
337	Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021, 18, 807-814.	1.5	4
338	Reply to Charles et al.. <i>Clinical Infectious Diseases</i> , 2009, 48, 1796-1797.	2.9	3
339	Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria. <i>Journal of Immunology Research</i> , 2015, 2015, 1-3.	0.9	3
340	Prone position and VAP incidence in the PROSEVA trial: attention to the causal question when interpreting competing risk analysis. <i>Intensive Care Medicine</i> , 2016, 42, 2119-2120.	3.9	3
341	Noninvasive Ventilation with Helium/Oxygen in Chronic Obstructive Pulmonary Disease Exacerbations. When Physiologic Improvement Does Not Translate into Clinical Benefit. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 843-844.	2.5	3
342	Hospitalized acute exacerbations of chronic obstructive pulmonary disease: which patients may have a negative clinical outcome?. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 691-693.	1.0	3

#	ARTICLE	IF	CITATIONS
343	Feasibility of computerized adventitious respiratory sounds to assess the effects of airway clearance techniques in patients with bronchiectasis. <i>Physiotherapy Theory and Practice</i> , 2020, 36, 1245-1255.	0.6	3
344	How may we improve clinical outcomes for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease? A narrative review about possible therapeutic and preventive strategies. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 493-500.	1.0	3
345	Reliability and Minimum Important Difference of Sputum Weight in Bronchiectasis. <i>Respiratory Care</i> , 2020, 65, 1478-1487.	0.8	3
346	Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 759-767.	2.0	3
347	Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 258-259.	2.5	3
348	Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study. <i>European Respiratory Journal</i> , 2022, 59, 2100620.	3.1	3
349	Too Much or Too Little Empiric Treatment for <i>Pseudomonas aeruginosa</i> in Community-acquired Pneumonia?. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1456-1458.	1.5	3
350	A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. <i>Journal of Medical Microbiology</i> , 2020, 69, 625-630.	0.7	3
351	COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital. <i>Pneumon</i> , 2021, , 1-6.	0.6	3
352	Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 149-161.	0.7	3
353	Predicting Community-Acquired Pneumonia Etiology: Response. <i>Chest</i> , 2013, 144, 1976.	0.4	2
354	IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia. <i>Journal of Clinical Virology</i> , 2014, 59, 135-136.	1.6	2
355	Respiratory infections management: Still a challenge. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 117-118.	1.1	2
356	Pneumonia in 2016: towards better care. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 949-951.	5.2	2
357	The clinical management of lower respiratory tract infections. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 441-452.	1.0	2
358	Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century. <i>Breathe</i> , 2017, 13, 209-215.	0.6	2
359	Rapid identification of antimicrobial resistance patterns allows a faster antibiotic adequacy. <i>Critical Care</i> , 2017, 21, 208.	2.5	2
360	New Insights into the Regulation of Endothelial Lung Permeability in Pneumonia. The Interplay between Angiotensin 1 and 2. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 149-150.	2.5	2

#	ARTICLE	IF	CITATIONS
361	The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 64-66.	0.8	2
362	Looking for Predictors of Early Readmission in Chronic Obstructive Pulmonary Disease: Every Effort Is Required. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1366-1366.	1.5	2
363	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1950.	1.0	2
364	The European Network for ICU-Related Respiratory Infections (ENIRRI) ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2019, 53, 1801972.	3.1	2
365	Aetiological diagnosis in new adult outpatients with bronchiectasis: role of predictors derived from real life experience. <i>Respiratory Medicine</i> , 2020, 172, 106090.	1.3	2
366	Noninvasive Ventilation and High-Flow Nasal Therapy Administration in Chronic Obstructive Pulmonary Disease Exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 786-797.	0.8	2
367	Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2884.	1.0	2
368	Association between sepsis at ICU admission and mortality in patients with ICU-acquired pneumonia: An infectious second-hit model. <i>Journal of Critical Care</i> , 2020, 59, 207-214.	1.0	2
369	Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, butâ€¦. <i>Clinical Infectious Diseases</i> , 2021, 72, 1990-1991.	2.9	2
370	Shifting the paradigm: unilateral infiltrates and ARDS?. <i>European Respiratory Journal</i> , 2021, 57, 2100043.	3.1	2
371	Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study. <i>Antibiotics</i> , 2021, 10, 798.	1.5	2
372	Design and Rationale of a Prospective International Follow-Up Study on Intensive Care Survivors of COVID-19: The Long-Term Impact in Intensive Care Survivors of Coronavirus Disease-19â€œAFTERCOR. <i>Frontiers in Medicine</i> , 2021, 8, 738086.	1.2	2
373	Corticosteroids for severe CAP: the pros. <i>Revista Brasileira De Terapia Intensiva</i> , 2015, 27, 202-4.	0.1	2
374	Development and characterization of a new swine model of invasive pneumococcal pneumonia. <i>Lab Animal</i> , 2021, 50, 327-335.	0.2	2
375	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health. <i>Journal of Mental Health</i> , 2022, 31, 524-533.	1.0	2
376	Ceftaroline in severe community-acquired pneumonia. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 28-30.	0.5	2
377	Pathophysiology of Pneumonia. , 0, , 63-78.		1
378	Epidemiology of Community-Acquired Pneumonia Outside Hospital. , 0, , 1-4.		1

#	ARTICLE	IF	CITATIONS
379	Non-Responding Pneumonia. , 0, , 213-227.		1
380	Reply to van Saene et al.. Intensive Care Medicine, 2009, 35, 1817-1817.	3.9	1
381	Influenza A (H1N1) Pneumonia. Clinical Pulmonary Medicine, 2012, 19, 246-253.	0.3	1
382	DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD TO DETERMINE VANCOMYCIN CONCENTRATIONS IN PLASMA AND PIG PULMONARY TISSUE. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 240-257.	0.5	1
383	Author's response to "CAP and HCAP are different? An unresolved question". Thorax, 2014, 69, 677-678.	2.7	1
384	Importance of a registered and structured protocol when conducting systematic reviews: comments about nebulized antibiotics for ventilator-associated pneumonia. Critical Care, 2015, 19, 298.	2.5	1
385	Mortality of CAP reduced in the UK: is this enough?. Thorax, 2016, 71, 979-980.	2.7	1
386	Has Mortality of Community-Acquired Pneumonia Really Reduced?. Clinical Pulmonary Medicine, 2017, 24, 258-262.	0.3	1
387	Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART. Current Infectious Disease Reports, 2018, 20, 46.	1.3	1
388	Community-acquired Pneumonia and Acute Respiratory Distress Syndrome: Prevalence, Risk, and Prognosis. Clinical Pulmonary Medicine, 2018, 25, 100-106.	0.3	1
389	Addendum: Cilloniz, C.; Dominedo, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49. Microorganisms, 2019, 7, 168.	1.6	1
390	Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia. Expert Opinion on Pharmacotherapy, 2019, 20, 1439-1448.	0.9	1
391	24th International Symposium on Infections in the Critically Ill Patient. Medical Sciences (Basel.) Tj ETQq1 1 0.784314 rgBT /Overlock	1.3	1
392	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. Journal of Medical Economics, 2020, 23, 148-155.	1.0	1
393	Reply to Musher. Journal of Infectious Diseases, 2020, 222, 334-335.	1.9	1
394	Characteristics and Outcomes in Patients with Ventilator-Associated Pneumonia Who Do or Do Not Develop Acute Respiratory Distress Syndrome. An Observational Study. Journal of Clinical Medicine, 2020, 9, 3508.	1.0	1
395	Ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2020, 33, 1.	1.3	1
396	The safety of antimicrobials for the treatment of community-acquired pneumonia. Expert Opinion on Drug Safety, 2020, 19, 577-587.	1.0	1

#	ARTICLE	IF	CITATIONS
397	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	1
398	What's Next in Pneumonia?. <i>Archivos De Bronconeumologia</i> , 2022, 58, 208-210.	0.4	1
399	Microbiological Diagnosis of Respiratory Infections in the Immunocompromised. , 0, , 29-52.		1
400	Diagnosis of Pneumonia in Immunocompromised Patient. , 0, , 53-93.		1
401	Respiratory Infections Following Haematopoietic Stem Cell Transplantation. , 0, , 213-256.		1
402	Chronic Non-Infectious Pulmonary Complications in Haematopoietic Stem Cell Transplantation. , 0, , 257-281.		1
403	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. , 2017, , .		1
404	Biomarkers in community-acquired pneumonia: can we do better by using them correctly?. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190189.	0.4	1
405	Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia. <i>Minerva Pneumologica</i> , 2019, 58, .	1.6	1
406	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 271-279.	1.3	1
407	Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia after Guidelines. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, , .	0.8	1
408	Pulmonary Infections in HIV Patients in the Highly Active Antiretroviral Therapy Era. , 0, , 117-141.		1
409	Empirical Treatment of Community-Acquired Pneumonia: Current Guidelines. , 0, , 63-100.		0
410	General Pharmacological Considerations in Antibiotic Treatment of Community-Acquired Pneumonia. , 0, , 127-152.		0
411	Î²-Lactams in the Therapy of Community-Acquired Pneumonia. , 0, , 153-169.		0
412	Macrolides and Ketolides. , 0, , 171-191.		0
413	Role of Fluoroquinolones in the Treatment of Community-Acquired Pneumonia. , 0, , 193-212.		0
414	Epidemiology of Adult Hospitalized Community-Acquired Pneumonia. , 0, , 5-19.		0

#	ARTICLE	IF	CITATIONS
415	Pathogen Directed Antimicrobial Treatment of Pneumonia. , 0, , 101-126.		0
416	Adjunctive Therapy in Community-Acquired Pneumonia. , 0, , 245-262.		0
417	Microbiological Diagnosis of Community-Acquired Pneumonia. , 0, , 43-61.		0
418	Microbial Aetiology and Antibiotic Resistances in Community-Acquired Pneumonia. , 0, , 21-41.		0
419	Influenza and Pneumococcal Vaccination for Prevention of Community-Acquired Pneumonia in Immunocompetent Adults. , 0, , 229-244.		0
420	Assisted Ventilation. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 407-408.	0.8	0
421	Treatment for Hospitalized Patients With Severe Community-Acquired Pneumoniaâ€”Reply. JAMA - Journal of the American Medical Association, 2015, 313, 2184.	3.8	0
422	Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients. European Respiratory Journal, 2016, 47, 1060-1061.	3.1	0
423	Response. Chest, 2016, 150, 757.	0.4	0
424	Community acquired pneumonia in asthma: Not a threatening combination. Respiratory Medicine, 2016, 112, 136.	1.3	0
425	Risk factors for community-acquired pneumonia in adults. Minerva Respiratory Medicine, 2017, 56, .	0.1	0
426	Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress. Journal of Thoracic Disease, 2017, 9, S1559-S1562.	0.6	0
427	COPD 2017: A Year in Review. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 118-122.	0.7	0
428	Response. Chest, 2019, 156, 415.	0.4	0
429	Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia. Journal of Clinical Medicine, 2019, 8, 1150.	1.0	0
430	Letter from Spain. Respiriology, 2019, 24, 817-818.	1.3	0
431	Reply to Head and Keynan. Clinical Infectious Diseases, 2019, 68, 1433-1434.	2.9	0
432	COPD in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 785-785.	0.8	0

#	ARTICLE	IF	CITATIONS
433	Respuesta a «Dual antibiotic therapy for outpatient management of community-acquired pneumonia?». Archivos De Bronconeumologia, 2020, 56, 766-767.	0.4	0
434	Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome. Archivos De Bronconeumologia, 2021, , .	0.4	0
435	Pulse oximetry is an essential tool that saves lives: a call for standardisation. European Respiratory Journal, 2021, 57, 2100815.	3.1	0
436	Cardiovascular Events during and after Bronchiectasis Exacerbations and Long-Term Mortality. Chest, 2021, , .	0.4	0
437	A new molecular diagnostic tool for pneumocystis jirovecii-pneumonia (PJP) detection: Results from European multicenter clinical study CS-2011.. Journal of Clinical Oncology, 2013, 31, e20652-e20652.	0.8	0
438	Personalizing pneumococcal vaccination recommendations: The Saudi Thoracic Society guidelines. Annals of Thoracic Medicine, 2016, 11, 89.	0.7	0
439	Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning. European Respiratory Journal, 2019, 54, 1902111.	3.1	0
440	Defining Clinical and Microbiological Nonresponse in Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2022, , .	0.8	0
441	Diagnóstico de la neumonía: una necesidad compartida. Enfermedades Infecciosas Y Microbiología Clínica, 2023, 41, 57-58.	0.3	0
442	New Antivirals and Immune Therapies for COVID-19 Infection. Archivos De Bronconeumologia, 2022, , .	0.4	0
443	Lung Immune Defences in the Immunosuppressed Patient. , 0, , 1-28.		0
444	Pulmonary Infections in Patients on Chronic Glucocorticoid Treatment. , 0, , 283-304.		0
445	Intensive Care Management in the Immunocompromised Patient with Pulmonary Infiltrates. , 0, , 305-323.		0
446	Current Strategies in the Treatment of Fungal Infections in the Intensive Care Unit Setting. , 0, , 349-381.		0
447	Current Strategies and Future Directions in Cytomegalovirus (CMV) Pneumonitis. , 0, , 383-400.		0
448	Antiviral Agents against Respiratory Viruses. , 0, , 401-428.		0
449	Pulmonary Imaging in Immunocompromised Patients. , 0, , 95-116.		0
450	Neutropenia. , 0, , 143-196.		0

#	ARTICLE	IF	CITATIONS
451	General Management of Suspected Pneumonia in the Solid Organ Transplant Patient. , 0, , 197-212.		0